問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of Ophthalmology

China Medical University Hospital (在職)

Division of Ophthalmology

更新時間：2023-09-19

陳珊霓Chen, San-Ni
  • Principal Investigator
  • Clinical Trial Experience (year)

  • 099390@tool.caaumed.org.tw

Recruiting Trial

8Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳珊霓

List

20Cases

2019-03-01 - 2023-12-31

Phase III

Completed
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (LUCERNE)

  • Condition/Disease

    nAMD

  • Test Drug

    Faricimab (RO6867461) Eylea

Participate Sites
4Sites

Terminated4Sites

2020-09-01 - 2024-10-09

Phase III

Completed
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion

  • Condition/Disease

    Macular Edema Secondary to Branch Retinal Vein Occlusion

  • Test Drug

    FARICIMAB (RO6867461)

Participate Sites
4Sites

Not yet recruiting4Sites

2020-09-01 - 2024-09-18

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-05-01 - 2024-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2025-02-03 - 2029-12-31

Others

Active
A PHASE IIIB/IV, MULTICENTER, RANDOMIZED, OPEN-LABEL, TWO-ARM STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND DURABILITY OF FARICIMAB ADMINISTERED UP TO EVERY 24 WEEKS IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (CONSTANCE)

  • Condition/Disease

    Evaluate the efficacy of intravitreal (IVT) faricimab in the study eye for each treatment group, based on the mean change from baseline in best-corrected visual acuity (BCVA) at Weeks 44, 48, and 52.

  • Test Drug

    Injection

Participate Sites
3Sites

Recruiting3Sites

2022-08-01 - 2027-06-30

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2024-02-01 - 2026-06-30

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-08-20 - 2024-08-07

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2009-04-01 - 2010-02-01

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2006-09-01 - 2010-03-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB